ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Jianqing Xu
Matched on ORCID iD 0000-0003-0896-9273; OpenAlex author ID A5003298311. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper
Papers 5
- CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. Co-author DOI 10.1002/ctm2.70501↗
- Exosomal lncRNA LINC01268 promotes pancreatic cancer progression via the miR-217-KIF2A-PI3K/AKT axis. Co-author DOI 10.1016/j.gendis.2022.12.018↗
- Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV… Last author DOI 10.1158/2767-9764.crc-23-0137↗
- Targeting cluster of differentiation 47 improves the efficacy of anti-cytotoxic T-lymphocyte associated protein 4 treatment via antigen presentation enhancemen… Last author DOI 10.3892/etm.2020.9054↗
- Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. Co-author DOI 10.18632/oncotarget.15148↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jin Wang · 3 shared papers, 2017–2025 · strength 0.46
- Paper CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. DOI 10.1002/ctm2.70501↗
- Paper Exosomal lncRNA LINC01268 promotes pancreatic cancer progression via the miR-217-KIF2A-PI3K/AKT axis. DOI 10.1016/j.gendis.2022.12.018↗
- Paper Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. DOI 10.18632/oncotarget.15148↗
- Xiaomeng He · 2 shared papers, 2023–2025 · strength 0.40
- Li Xu · 1 shared paper, 2025 · strength 0.22
- Di Yang · 1 shared paper, 2025 · strength 0.22
- Wenchuan Wu · 1 shared paper, 2025 · strength 0.22
- Xifu Song · 1 shared paper, 2020 · strength 0.19
- Shanshan Liu · 1 shared paper, 2023 · strength 0.18
- Xiaoyan Zhang · 1 shared paper, 2023 · strength 0.17
- Jing Wang · 1 shared paper, 2023 · strength 0.17
- Wei Zhang · 1 shared paper, 2023 · strength 0.17
- Zenglin Pei · 1 shared paper, 2017 · strength 0.06
- Dong Yan · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.